Journal
PHARMACOLOGY & THERAPEUTICS
Volume 232, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2021.107992
Keywords
Ferroptosis; Breast cancer; Glutathione; Glutathione peroxidase 4; Iron; Nuclear factor erythroid-2 related factor-2; Superoxide dismutases; Lipoxygenase; Coenzyme Q
Categories
Funding
- ProjectNn10 ofHarbin Medical University Cancer Hospital [Nn102017-02]
- National Natural Science Foundation of China [81602323, 81872149]
- Outstanding Youth Project of Heilongjiang Provincial Natural Science Foundation [YQ2019H027]
- Distinguished Young Scholars of Harbin Medical University Cancer Hospital [JCQN2018-03]
- Yong Elite Training Foundation Grant of Harbin Medical University Cancer Hospital [JY2016-02]
- Heilongjiang Postdoctoral Fund [LBH-Z20080]
- China Postdoctoral Science Foundation [2021M693827]
- Outstanding Project ofHaiyan Fund of HarbinMedical University Cancer Hospital [JJZD2021-12]
- Innovation Fund of Harbin Medical University [2020-kyywf-1467]
Ask authors/readers for more resources
Breast cancer is a significant threat to women's health, and ferroptosis may offer a new direction for breast cancer treatment. However, the complete appearance of ferroptosis in breast cancer and its potential combination with traditional anti-breast cancer drugs remain uncertain. This review explores the roles of various factors associated with ferroptosis in breast cancer, provides evidence of ferroptosis induction by traditional drugs and elimination of breast cancer cells by ferroptosis inducers, and discusses the prospects and potential obstacles of using ferroptosis inducers in breast cancer therapy.
Breast cancer has become a serious threat to women's health. Cancer progression is mainly derived from resistance to apoptosis induced by procedures or therapies. Therefore, new drugs or models that can overcome apoptosis resistance should be identified. Ferroptosis is a recently identified mode of cell death characterized by excess reactive oxygen species-induced lipid peroxidation. Since ferroptosis is distinct from apoptosis, necrosis and autophagy, its induction successfully eliminates cancer cells that are resistant to other modes of cell death. Therefore, ferroptosis may become a new direction around which to design breast cancer treatment. Unfortunately, the complete appearance of ferroptosis in breast cancer has not yet been fully elucidated. Furthermore, whether ferroptosis inducers can be used in combination with traditional anti- breast cancer drugs is still unknown. Moreover, a summary of ferroptosis in breast cancer progression and therapy is currently not available. In this review, we discuss the roles of ferroptosis-associated modulators glutathione, glutathione peroxidase 4, iron, nuclear factor erythroid-2 related factor-2, superoxide dismutases, lipoxygenase and coenzyme Q in breast cancer. Furthermore, we provide evidence that traditional drugs against breast cancer induce ferroptosis, and that ferroptosis inducers eliminate breast cancer cells. Finally, we put forward prospect of using ferroptosis inducers in breast cancer therapy, and predict possible obstacles and corresponding solutions. This review will deepen our understanding of the relationship between ferroptosis and breast cancer, and provide new insights into breast cancer-related therapeutic strategies. (C) 2021 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available